[go: up one dir, main page]

MX2017013350A - Comprimido de ribociclib. - Google Patents

Comprimido de ribociclib.

Info

Publication number
MX2017013350A
MX2017013350A MX2017013350A MX2017013350A MX2017013350A MX 2017013350 A MX2017013350 A MX 2017013350A MX 2017013350 A MX2017013350 A MX 2017013350A MX 2017013350 A MX2017013350 A MX 2017013350A MX 2017013350 A MX2017013350 A MX 2017013350A
Authority
MX
Mexico
Prior art keywords
ribociclib
tablet
directed
present disclosure
coating
Prior art date
Application number
MX2017013350A
Other languages
English (en)
Inventor
Grandeury Arnaud
Gururajan Bindhumadhavan
Costa Rui
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=55806565&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2017013350(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of MX2017013350A publication Critical patent/MX2017013350A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente descripción está dirigida al comprimido oral de ribociclib incluyendo su(s) sal(es). Una modalidad de la presente descripción se dirige al comprimido de ribociclib con alta carga de fármaco con un perfil de liberación inmediata. Una modalidad de la presente descripción se refiere a un comprimido de ribociclib recubierto. Otra modalidad de la presente descripción se refiere a un comprimido de ribociclib recubierto donde el recubrimiento es una barrera contra la humedad avanzada (por ejemplo, el recubrimiento Opadry(r) amb II donde el recubrimiento está basado en PVA).
MX2017013350A 2015-04-16 2016-04-14 Comprimido de ribociclib. MX2017013350A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562148240P 2015-04-16 2015-04-16
PCT/IB2016/052136 WO2016166703A1 (en) 2015-04-16 2016-04-14 Ribociclib tablet

Publications (1)

Publication Number Publication Date
MX2017013350A true MX2017013350A (es) 2018-01-25

Family

ID=55806565

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017013350A MX2017013350A (es) 2015-04-16 2016-04-14 Comprimido de ribociclib.

Country Status (29)

Country Link
US (6) US10799506B2 (es)
EP (3) EP4620458A3 (es)
JP (1) JP2018514523A (es)
KR (2) KR102750931B1 (es)
CN (2) CN115554257A (es)
AR (1) AR104257A1 (es)
AU (5) AU2016248017A1 (es)
BR (1) BR112017021283A2 (es)
CA (1) CA2982425C (es)
CL (1) CL2017002593A1 (es)
CO (1) CO2017010510A2 (es)
DK (1) DK3283058T3 (es)
EA (1) EA201792290A1 (es)
EC (1) ECSP17075052A (es)
ES (1) ES2938261T3 (es)
FI (1) FI3283058T3 (es)
HR (1) HRP20230053T1 (es)
HU (1) HUE061213T2 (es)
IL (1) IL254818A0 (es)
MX (1) MX2017013350A (es)
PE (1) PE20180035A1 (es)
PH (1) PH12017501820A1 (es)
PL (1) PL3283058T3 (es)
PT (1) PT3283058T (es)
SG (1) SG11201708084PA (es)
SI (1) SI3283058T1 (es)
TN (1) TN2017000422A1 (es)
TW (1) TW201642864A (es)
WO (1) WO2016166703A1 (es)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2938261T3 (es) * 2015-04-16 2023-04-05 Novartis Ag Comprimido de ribociclib
CA3048036A1 (en) 2018-07-02 2020-01-02 Apotex Inc Novel crystalline form of ribociclib succinate
KR20220054347A (ko) 2019-08-26 2022-05-02 아비나스 오퍼레이션스, 인코포레이티드 에스트로겐 수용체 분해제로서의 테트라히드로나프탈렌 유도체로 유방암을 치료하는 방법
CA3164617A1 (en) 2019-12-16 2021-06-24 Lunella Biotech, Inc. Selective cdk4/6 inhibitor cancer therapeutics
JP7657222B2 (ja) 2019-12-16 2025-04-04 ルネラ・バイオテック・インコーポレーテッド 選択的ｃｄｋ４／６阻害剤のがん治療薬
WO2022029798A1 (en) * 2020-08-03 2022-02-10 Natco Pharma Limited Pharmaceutical compositions comprising ribociclib
WO2022071787A1 (es) * 2020-09-29 2022-04-07 Laboratorios Silanes S.A. De C.V. Combinaciones farmacéuticas de estatinas y fibratos para el tratamiento y prevención de hiperlipidemias y enfermedades cardiovasculares
WO2022162122A1 (en) 2021-01-29 2022-08-04 Biotx.Ai Gmbh Genetically verified netosis inhibitor for use in the treatment of a sars-cov2 infection
JP2024525740A (ja) 2021-07-16 2024-07-12 ダナ－ファーバー キャンサー インスティテュート，インコーポレイテッド 小分子サイクリン依存性キナーゼ４／６（ｃｄｋ４／６）およびｉｋｚｆ２（ｈｅｌｉｏｓ）分解剤並びにその使用方法
TWI848533B (zh) 2022-01-25 2024-07-11 瑞士商諾華公司 瑞博西尼藥物組成物
TW202539669A (zh) 2022-08-31 2025-10-16 美商亞文納營運公司 雌激素受體降解劑之給藥方案
EP4626890A1 (en) 2022-12-01 2025-10-08 KRKA, d.d., Novo mesto Ribociclib salts and formulations thereof
WO2024201299A1 (en) 2023-03-27 2024-10-03 Novartis Ag Method of treating early breast cancer with ribociclib in combination with an aromatase inhibitor
WO2025219830A1 (en) 2024-04-15 2025-10-23 Novartis Ag Pharmaceutical compositions of ribociclib

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5428812A (en) * 1977-08-09 1979-03-03 Yoshitomi Pharmaceut Ind Ltd Preparation of coated tablet
GB9414045D0 (en) 1994-07-12 1994-08-31 Berwind Pharma Service Moisture barrier film coating composition, method, and coated form
AU703933B2 (en) * 1994-07-12 1999-04-01 Berwind Pharmaceutical Services, Inc. Moisture barrier film coating composition, method, and coated form
US6448323B1 (en) * 1999-07-09 2002-09-10 Bpsi Holdings, Inc. Film coatings and film coating compositions based on polyvinyl alcohol
PT2331547E (pt) 2008-08-22 2014-10-29 Novartis Ag Compostos de pirrolopirimidina como inibidores de cdk
US8343533B2 (en) * 2009-09-24 2013-01-01 Mcneil-Ppc, Inc. Manufacture of lozenge product with radiofrequency
US20120115878A1 (en) 2010-11-10 2012-05-10 John Vincent Calienni Salt(s) of 7-cyclopentyl-2-(5-piperazin-1-yl-pyridin-2-ylamino)-7h-pyrrolo[2,3-d]pyrimidine-6-carboxylic acid dimethylamide and processes of making thereof
PL2673266T3 (pl) * 2011-02-11 2017-01-31 Wista Lab Ltd Fenotiazynowe sole diaminiowe i ich zastosowanie
CN108143728A (zh) * 2012-07-13 2018-06-12 Gtx公司 选择性雄激素受体调节剂在治疗乳癌中的用途
EP2742940B1 (en) 2012-12-13 2017-07-26 IP Gesellschaft für Management mbH Fumarate salt of (R)-3-(6-(4-methylphenyl)-pyridin-3-yloxy)-l-aza-bicyclo-[2.2.2]octane for adminstration once daily, twice daily or thrice daily
EP2934515B1 (en) * 2012-12-20 2018-04-04 Novartis AG A pharmaceutical combination comprising binimetinib
CA2907704C (en) * 2013-03-21 2023-01-10 Giordano Caponigro Combination therapy for reversing b-raf inhibitor resistance comprising a second inhibitor based on genetic alterations
EP2810644A1 (en) * 2013-06-06 2014-12-10 Ferrer Internacional, S.A. Oral formulation for the treatment of cardiovascular diseases
ES2938261T3 (es) 2015-04-16 2023-04-05 Novartis Ag Comprimido de ribociclib
CN109953966A (zh) * 2017-12-26 2019-07-02 天津耀辰实业发展有限公司 一种含有瑞博西尼的药物组合物及其制备方法
JP7347388B2 (ja) 2020-09-25 2023-09-20 信越化学工業株式会社 紫外線硬化型有機変性シリコーン組成物および硬化物

Also Published As

Publication number Publication date
US20200390771A1 (en) 2020-12-17
SG11201708084PA (en) 2017-10-30
AU2020250190A1 (en) 2020-11-05
AU2019201929A1 (en) 2019-04-11
US20250134893A1 (en) 2025-05-01
US10799506B2 (en) 2020-10-13
IL254818A0 (en) 2017-12-31
CN115554257A (zh) 2023-01-03
AU2024227794A1 (en) 2024-11-21
US12419894B2 (en) 2025-09-23
US20180071292A1 (en) 2018-03-15
KR20170137101A (ko) 2017-12-12
EP4620458A3 (en) 2025-10-22
JP2018514523A (ja) 2018-06-07
EP3283058B1 (en) 2022-11-16
DK3283058T3 (da) 2023-02-13
CA2982425C (en) 2023-10-31
EA201792290A1 (ru) 2018-02-28
BR112017021283A2 (pt) 2018-06-26
ES2938261T3 (es) 2023-04-05
PT3283058T (pt) 2023-02-03
FI3283058T3 (fi) 2023-03-01
AU2019201929B2 (en) 2020-07-09
EP4620458A2 (en) 2025-09-24
CA2982425A1 (en) 2016-10-20
EP3283058A1 (en) 2018-02-21
CL2017002593A1 (es) 2018-05-18
AU2022215155B2 (en) 2024-08-01
HUE061213T2 (hu) 2023-05-28
ECSP17075052A (es) 2018-02-28
EP4197530B1 (en) 2025-11-12
CO2017010510A2 (es) 2018-03-20
US20230104792A1 (en) 2023-04-06
HRP20230053T1 (hr) 2023-03-03
US20250127785A1 (en) 2025-04-24
AU2022215155A1 (en) 2022-09-01
CN107530292A (zh) 2018-01-02
KR20250009572A (ko) 2025-01-17
PE20180035A1 (es) 2018-01-09
AR104257A1 (es) 2017-07-05
EP4197530A1 (en) 2023-06-21
KR102750931B1 (ko) 2025-01-09
CN107530292B (zh) 2022-11-01
TW201642864A (zh) 2016-12-16
WO2016166703A1 (en) 2016-10-20
TN2017000422A1 (en) 2019-01-16
US20250090531A1 (en) 2025-03-20
SI3283058T1 (sl) 2023-03-31
PL3283058T3 (pl) 2023-03-20
AU2016248017A1 (en) 2017-10-19
PH12017501820A1 (en) 2018-04-23
US12064434B2 (en) 2024-08-20

Similar Documents

Publication Publication Date Title
PH12017501820A1 (en) Ribociclib tablet
EP3246328A4 (en) Quinazoline heterocyclic compound as egfr kinase inhibitor, and preparation and application thereof
EP3278803A4 (en) Solid pharmaceutical dosage form of parp inhibitor, and application of solid pharmaceutical dosage form of parp inhibitor
WO2017075629A3 (en) Wee 1 kinase inhibitors and methods of making and using the same
EP3130592A4 (en) Analogues of 4h-pyrazolo[1,5- ]benzimidazole compound as parp inhibitors
IL280641A (en) Converted benzimidazoles as PAD4 inhibitors
EP3290420A4 (en) Pyrimidine pyrrole compound, preparation method therefor, pharmaceutical composition, and uses thereof
IN2015DN01286A (es)
PH12015502783A1 (en) Delayed release cysteamine bead formulation
EP3124486A4 (en) Substituted nitrogen-containing heterocyclic derivatives, pharmaceutical compositions comprising the same and applications of antitumor thereof
EP3252118A4 (en) Aqueous coating composition
EP3630113A4 (en) PHARMACEUTICAL COMPOSITION INCLUDING A PDE9 INHIBITOR
EP3256672A4 (en) Access-control fixture lock
EP3078671A4 (en) Gemcitabine derivative, composition containing the derivative and pharmaceutical use of the derivative
SG11201705533SA (en) Levelling compound, its use and manufacture
GB2543709A (en) Pharmaceutical agent
MX372834B (es) PREPARACION FARMACEUTICA COMBINADA QUE COMPRENDE EL BLOQUEANTE DEL RECEPTOR DE LA ANGIOTENSINA II Y EL INHIBIDOR DE LA HMG-CoA REDUCTASA.
EP3325564A4 (en) AQUEOUS COATING COMPOSITION
CY1120192T1 (el) Ενωσεις για την ενισχυση της γνωστικης λειτουργιας
EP3303319B8 (en) Derivatives of 1,2,3-triazolyl cyclohexan-1-ol and its use
EP3024427A4 (en) Derivatives of 2,2,6-trimethylcyclohexane-carboxylate
JO3298B1 (ar) مشتقات جليكوبيرانوسيل-مستبدل و اندول-يوريا و استعمالاتهم كمثبطات sglt
MX356027B (es) Composiciones para cuidado oral y metodos.
EP3253202A4 (en) Acid herbicide-containing compositions, precursors, derivatives, and methods
HK40054295A (en) Substituted benzimidazoles as pad4 inhibitors